BioSpace News Archive

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 6th Annual Israel Conference.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equillium’s chief executive officer and Krishna Polu, M.D., Equillium’s chief medical officer, will present at two upcoming investor conferences in November 2020.

Netcapital Inc. (OTC: VSTRD) announced that portfolio company Vymedic’s clinically proven antiviral will be delivered to market this December, in time for flu season

DURECT Corporation announced that Norman Sussman, MD, FAASLD, newly appointed Chief Medical Officer, will host a webinar on the treatment landscape and unmet medical need in treating patients with alcoholic hepatitis, as well as information on DURECT’ investigational drug candidate, DUR-928, being developed for the treatment of AH.

Event will review two decades of Tumor Treating Fields research and introduce exciting new directions of ongoing research and development

icotec ag, the leading medical device manufacture of Carbon/PEEK spinal implants, announces the U.S. Food and Drug Administration 510 clearance to market the VADER® Pedicle - System for use with bone cement for augmentation or without.

NINDS Small Business Innovation Research grant of $670K over two years to support CODA’s neuropathic pain program Company also selected for collaboration with NIH’s National Center for Advancing Translational Science

Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:00 p.m. ET. A live audio webcast of the presentation wi

Oryzon announced today that it has received approval from the Spanish Drug Agency (AEMPS) for its Clinical Trial Application (CTA) to conduct a Phase IIb clinical trial with vafidemstat in patients with Borderline Personality Disorder (BPD).

Selecta Biosciences, Inc. announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in November: